Liu Wei, Cui Lei, Cao Yilin
Department of Plastic Surgery, Shanghai 9th People's Hospital, Shanghai, People's Republic of China.
Methods Enzymol. 2006;420:362-80. doi: 10.1016/S0076-6879(06)20017-X.
Bone marrow stromal/stem cells (BMSCs) are multipotent adult stem cells and have become the important cell source for cell therapy and engineered tissue repair. Their osteogenic differentiation potential has been well characterized in many in vitro studies. In addition, small animal model-based studies also reveal their capability of bone formation in vivo when implanted with biodegradable scaffold, indicating the great potential for therapeutic application. Bone defect is a common clinical problem that deserves an optimal therapy. Unlike traditional surgical repair that needs to sacrifice donor site tissue, the tissue-engineering approach can achieve the goal of bone regeneration and repair without the necessity of donor site morbidity. To safely translate experimental study into a clinical trial of engineered bone repair, in vivo study using large animal models has become the key issue. Our in vivo study in this aspect and the published results indicate that bone regeneration and repair by BMSCs and biodegradable scaffold is a realistic goal that can be achieved.
骨髓基质/干细胞(BMSCs)是多能成体干细胞,已成为细胞治疗和组织工程修复的重要细胞来源。它们的成骨分化潜能在许多体外研究中已得到充分表征。此外,基于小动物模型的研究还揭示了在植入可生物降解支架时它们在体内形成骨的能力,这表明其具有巨大的治疗应用潜力。骨缺损是一个常见的临床问题,值得进行最佳治疗。与需要牺牲供体部位组织的传统手术修复不同,组织工程方法可以实现骨再生和修复的目标,而无需供体部位发病。为了将实验研究安全地转化为工程化骨修复的临床试验,使用大型动物模型的体内研究已成为关键问题。我们在这方面的体内研究以及已发表的结果表明,通过BMSCs和可生物降解支架实现骨再生和修复是一个可以实现的现实目标。